出版：Market Research Future（マーケットリサーチフューチャー） 出版年月：2021年08月
萎縮型加齢黄斑変性症市場：病期（初期型加齢黄斑変性症、中期型加齢黄斑変性症、後期型加齢黄斑変性症）、年齢層（75歳以上、60歳以上、40歳以上）、診断および治療別 [ 治療（栄養療法（ビタミン、亜鉛、銅）、伸縮レンズインプラント）、診断（フルオレセイン血管造影、予備試験、光コヒーレンストモグラフィー ]、投与経路（経口、注射剤）、エンドユーザー（病院,診療所、診断センター、アカデミックリサーチインスティテュート）、地域別（北米、ヨーロッパ、アジア太平洋、RoW）- 2027年までの予測
Dry Age-Related Macular Degeneration Market: Information by Stages (Early Age-Related Macular Degeneration, Intermediate Age-Related Macular Degeneration, and Late Age-Related Macular Degeneration), By Age Group (Above 75 Years, Above 60 Years, and Above 40 Years), By Diagnosis and Treatment[Treatment (Nutrition Therapy (Vitamins, Zinc, Copper), Telescopic Lens Implant), and Diagnosis (Fluorescein Angiogram, Preliminary Test, Optical Coherence Tomography], By Route of Administration (Oral, Injectables), by End User (Hospitals & Clinics, Diagnostic Centers, Academic Research Institutes), and by Region(North America, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2027
| ページ数 | 171 |
| 価格 | |
| シングルユーザライセンス | USD4,450 |
| エンタープライズライセンス | USD6,250 |
| 種別 | 英文調査報告書 |
Dry Age-Related Macular Degeneration Market—Forecast till 2027
Dry Age-Related Macular Degeneration AMD Market Forecast
According to market research future analysis, the global dry age-related macular degeneration AMD market is projected to witness a significant CAGR of 8.62% during the review period to surpass USD 6,113.33 million by the end of 2027. Dry macular degeneration is a typical eye issue among individuals aged more than 50. The macula is the piece of the retina answerable for clear vision in your immediate view.
The development of the worldwide dry Age-related Macular Degeneration (AMD) market is ascribed to the developing geriatric populace and expanding pervasiveness old enough related macular degeneration, and the presentation of novel treatment techniques for dry AMD combined with the expanding number of clinical preliminaries zeroed in on dry AMD. Different variables like expanding medical services use are probably going to assist the market with developing. In any case, a large number of bombed clinical preliminaries for dry AMD medications may hamper the market development somewhat. The global market expansion is propelled by the growing geriatric population and rising incidences of dry age-related macular degeneration.
Segment Overview
The global dry age-related macular degeneration AMD market has been divided based on stages, age group, route of administration, diagnosis & treatment, and end-user.
Based on Stages the global market has been classified into Early stage of AMD, Intermediate Stage of AMD, and Late Stage of AMD. By age group segment, the global market is categorized into above 75 years, above 60 years, and above 40 years.
In terms of diagnosis & treatment, the dry age-related macular degeneration AMD market is bifurcated into treatment and diagnosis. The treatment is further classified into nutrition therapy and telescopic lens implant. The nutrition therapy segment is sub-segmented into antioxidants and others. Based on the route of administration, the market is divided into oral and injectables. In terms of end-user, the market is categorized into hospitals &clinics, diagnostic centers, academic &research institutes, and others.
Regional Analysis
Based on region, the global dry AMD market has been classified into North America, Europe, Asia-Pacific, and the Rest of the World.
North America is likely to drive the largest market for global dry AMD owing to the government initiatives and funding in the region. Europe holds the second biggest portion of the overall industry because of the expanding more seasoned populace and rising patient populace. Furthermore, further developing government drives, expanding medical care casings, and rising interest for mechanically inventive therapy are driving the development of the dry age-related macular degeneration market in Europe. The Asia-Pacific exhibits the rapidly developing business sector for age-related macular degeneration as it is creating at an exceptionally fast speed and has shown the rise of numerous players.
Major Players
Major players of the global dry age-related macular degeneration AMD market are Santen Pharmaceuticals Inc. (Japan), Allergan plc (Ireland), Bausch Health (Canada), Alimera Science Inc. (US), Phio Pharmaceuticals Corp (US), Ocumension Therapeutics Co. Ltd (China), Belite Bio Inc. (US), Kubota Vision Inc. (US), Iveric Bio (US), Eyestem Research Pvt Ltd (India), Yuyang DNU Co., Ltd (South Korea), and Stealth Biotherapeutics Inc. (US)
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
目次
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY
2.2 RESEARCH OBJECTIVE
2.3 MARKET STRUCTURE
2.4 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 GROWING GERIATRIC POPULATION AND INCREASING PREVALENCE OF DRY AGE-RELATED MACULAR DEGENERATION
4.2.2 INCREASING HEALTHCARE EXPENDITURE
4.3 RESTRAINTS
4.3.1 FAILED CLINICAL TRAILS FOR DRY AMD
4.4 OPPORTUNITIES
4.4.1 INCREASE IN PIPELINE DRUGS FOR DRY AMD
4.4.2 DEVELOPMENT OF NEW TECHNOLOGIES FOR TREATMENT
4.5 EPIDEMIOLOGY OF DRY AMD
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION AND SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF BUYERS
5.2.3 THREAT OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTES
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE DRY AMD MARKET
5.3.1 OVERVIEW
5.3.2 IMPACT ON PATIENTS WITH DRY AMD
5.3.3 IMPACT ON CLINICAL TRIALS
5.3.4 IMPACT ON R&D
5.3.5 IMPACT ON MARKET GROWTH
6 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES
6.1 OVERVIEW
6.2 EARLY AGE-RELATED MACULAR DEGENERATION
6.3 INTERMEDIATE AGE-RELATED MACULAR DEGENERATION
6.4 LATE AGE-RELATED MACULAR DEGENERATION
7 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP
7.1 OVERVIEW
7.2 ABOVE 40 YEARS
7.3 ABOVE 60 YEARS
7.4 ABOVE 75 YEARS
8 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT
8.1 OVERVIEW
8.2 TREATMENT
8.3 DIAGNOSIS
9 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION
9.1 OVERVIEW
9.2 ORAL
9.3 INJECTABLES
10 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITAL & CLINICS
10.3 DIAGNOSTIC CENTERS
10.4 ACADEMIC RESEARCH INSTITUTES
10.5 OTHERS
11 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION
11.1 OVERVIEW
11.2 NORTH AMERICA
11.2.1 US
11.2.2 CANADA
11.3 EUROPE
11.3.1 GERMANY
11.3.2 UK
11.3.3 FRANCE
11.3.4 ITALY
11.3.5 SPAIN
11.3.6 REST OF EUROPE
11.4 ASIA-PACIFIC
11.4.1 CHINA
11.4.2 JAPAN
11.4.3 INDIA
11.4.4 SOUTH KOREA
11.4.5 AUSTRALIA
11.4.6 REST OF ASIA-PACIFIC
11.5 REST OF THE WORLD
11.5.1 MIDDLE EAST
11.5.2 AFRICA
11.5.3 LATIN AMERICA
12 COMPETITIVE LANDSCAPE
12.1 COMPETITIVEOVERVIEW
12.2 MARKET SHARE ANALYSIS
12.3 MAJOR GROWTH STRATEGIES IN THE GLOBAL DRY AMD MARKET
12.4 COMPETITIVE BENCHMARKING
12.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL DRY AMD MARKET
12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
12.6.1 CONTRACTS & AGREEMENTS
12.6.2 NEW PRODUCT DEVELOPMENTS/LAUNCHES
12.6.3 COLLABORATIONS/ EXPANSIONS/PARTNERSHIPS/JOINT VENTURES
12.6.4 INVESTMENT
12.7 MAJOR PLAYERS FINANCIAL MATRIX
12.7.1 SALES, 2020
12.7.2 R&D EXPENDITURE, 2020
13 COMPANY PROFILES
13.1 SANTEN PHARMACEUTICALS INC.
13.1.1 COMPANY OVERVIEW
13.1.2 FINANCIAL OVERVIEW
13.1.3 PRODUCTS/SERVICES OFFERED
13.1.4 KEY DEVELOPMENTS
13.1.5 SWOT ANALYSIS
13.1.6 KEY STRATEGIES
13.2 ALLERGAN PLC
13.2.1 COMPANY OVERVIEW
13.2.2 FINANCIAL OVERVIEW
13.2.3 PRODUCTS/SERVICES OFFERED
13.2.4 ALLERGAN: KEY DEVELOPMENTS
13.2.5 SWOT ANALYSIS
13.2.6 KEY STRATEGIES
13.3 BAUSCH HEALTH (VALEANT PHARMACEUTICALS)
13.3.1 COMPANY OVERVIEW
13.3.2 FINANCIAL OVERVIEW
13.3.3 PRODUCTS/SERVICES OFFERED
13.3.4 KEY DEVELOPMENTS
13.3.5 SWOT ANALYSIS
13.3.6 KEY STRATEGIES
13.4 ALIMERA SCIENCES INC.
13.4.1 COMPANY OVERVIEWS
13.4.2 FINANCIAL OVERVIEW
13.4.3 PRODUCTS/SERVICES OFFERED
13.4.4 KEY DEVELOPMENTS
13.4.5 SWOT ANALYSIS
13.4.6 KEY STRATEGIES
13.5 RXI PHARMACEUTICALS, INC. (PHIO PHARMACEUTICALS CORP)
13.5.1 COMPANY OVERVIEW
13.5.2 FINANCIAL OVERVIEW
13.5.3 PRODUCTS/SERVICES OFFERED
13.5.4 KEY DEVELOPMENTS
13.5.5 SWOT ANALYSIS
13.5.6 KEY STRATEGIES
13.6 OCUMENSION THERAPEUTICS (SHANGHAI) CO., LTD
13.6.1 COMPANY OVERVIEWS
13.6.2 FINANCIAL OVERVIEW
13.6.3 PRODUCTS/SERVICES OFFERED
13.6.4 KEY DEVELOPMENTS
13.6.5 SWOT ANALYSIS
13.6.6 KEY STRATEGIES
13.7 BELITE BIO INC.
13.7.1 COMPANY OVERVIEW
13.7.2 FINANCIAL OVERVIEW
13.7.3 PRODUCTS/SERVICES OFFERED
13.7.4 KEY DEVELOPMENTS
13.7.5 SWOT ANALYSIS
13.7.6 KEY STRATEGIES
13.8 KUBOTA VISION INC.
13.8.1 COMPANY OVERVIEW
13.8.2 FINANCIAL OVERVIEW
13.8.3 PRODUCTS/SERVICES OFFERED
13.8.4 KEY DEVELOPMENTS
13.8.5 SWOT ANALYSIS
13.8.6 KEY STRATEGIES
13.9 IVERIC BIO
13.9.1 COMPANY OVERVIEW
13.9.2 FINANCIAL OVERVIEW
13.9.3 PRODUCTS/SERVICES OFFERED
13.9.4 KEY DEVELOPMENTS
13.9.5 SWOT ANALYSIS
13.9.6 KEY STRATEGIES
13.10 EYESTEM RESEARCH PVT LTD
13.10.1 COMPANY OVERVIEW
13.10.2 FINANCIAL OVERVIEW
13.10.3 PRODUCTS/SERVICES OFFERED
13.10.4 KEY DEVELOPMENTS
13.10.5 SWOT ANALYSIS
13.10.6 KEY STRATEGIES
13.11 YUYANG DNU CO., LTD
13.11.1 COMPANY OVERVIEW
13.11.2 FINANCIAL OVERVIEW
13.11.3 PRODUCTS/SERVICES OFFERED
13.11.4 KEY DEVELOPMENTS
13.11.5 SWOT ANALYSIS
13.11.6 KEY STRATEGIES
13.12 STEALTH BIOTHERAPEUTICS CORP
13.12.1 COMPANY OVERVIEW
13.12.2 FINANCIAL OVERVIEW
13.12.3 PRODUCTS/SERVICES OFFERED
13.12.4 KEY DEVELOPMENTS
13.12.5 SWOT ANALYSIS
13.12.6 KEY STRATEGIES
14 APPENDIX
14.1 REFERENCES
14.2 RELATED REPORTS
LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
TABLE 3 DRY AMD DRUGS ONGOING CLINICAL TRIALS
TABLE 4 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018–2027 (USD MILLION)
TABLE 5 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR EARLY AMD, BY REGION, 2018–2027 (USD MILLION)
TABLE 6 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR INTERMEDIATE AMD, BY REGION, 2018–2027 (USD MILLION)
TABLE 7 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR LATE AMD, BY REGION, 2018–2027 (USD MILLION)
TABLE 8 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018–2027 (USD MILLION)
TABLE 9 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ABOVE 40 YEARS, BY REGION, 2018–2027 (USD MILLION)
TABLE 10 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR ABOVE 60 YEARS, BY REGION, 2018–2027 (USD MILLION)
TABLE 11 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR ABOVE 75 YEARS, BY REGION, 2018–2027 (USD MILLION)
TABLE 12 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION AMD MARKET, BY DIAGNOSIS AND TREATMENT, 2018–2027 (USD MILLION)
TABLE 13 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY REGION, 2018–2027 (USD MILLION)
TABLE 14 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, 2018–2027 (USD MILLION)
TABLE 15 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT TYPE, BY NUTRITION THERAPY, 2018–2027 (USD MILLION)
TABLE 16 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITIONAL THERAPY, BY ANTIOXIDANTS, 2018–2027 (USD MILLION)
TABLE 17 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY REGION, 2018–2027 (USD MILLION)
TABLE 18 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS, 2018–2027 (USD MILLION)
TABLE 19 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018–2027 (USD MILLION)
TABLE 20 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ORAL, BY REGION, 2018–2027 (USD MILLION)
TABLE 21 ONGOING CLINICAL TRIALS RELATED TO AGE-RELATED MACULAR DEGENERATION, BY ROUTE OF ADMINISTRATION, 2020
TABLE 22 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR INJECTABLES, BY REGION, 2018–2027 (USD MILLION)
TABLE 23 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 24 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR HOSPITAL & CLINICS, BY REGION, 2018–2027 (USD MILLION)
TABLE 25 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR DIAGNOSTIC CENTERS, BY REGION, 2018–2027 (USD MILLION)
TABLE 26 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018–2027 (USD MILLION)
TABLE 27 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR OTHERS, BY REGION, 2018–2027 (USD MILLION)
TABLE 28 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION, 2018–2027 ((USD MILLION)
TABLE 29 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018–2027 (USD MILLION)
TABLE 30 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018–2027 (USD MILLION)
TABLE 31 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018–2027 (USD MILLION)
TABLE 32 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, 2018–2027 (USD MILLION)
TABLE 33 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR TREATMENT, BY NUTRITION THERAPY, 2018–2027 (USD MILLION)
TABLE 34 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR NUTRITION THERAPY, BY ANTIOXIDANTS, 2018–2027 (USD MILLION)
TABLE 35 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS, 2018–2027 (USD MILLION)
TABLE 36 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018–2027 (USD MILLION)
TABLE 37 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 38 US: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018–2027 (USD MILLION)
TABLE 39 US: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018–2027 (USD MILLION)
TABLE 40 US: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018–2027 (USD MILLION)
TABLE 41 US: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, 2018–2027 (USD MILLION)
TABLE 42 US: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR TREATMENT TYPE, BY NUTRITION THERAPY, 2018–2027 (USD MILLION)
TABLE 43 US: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR A NUTRITION THERAPY, BY ANTIOXIDANTS, 2018–2027 (USD MILLION)
TABLE 44 US: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS, 2018–2027 (USD MILLION)
TABLE 45 US: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018–2027 (USD MILLION)
TABLE 46 US: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 47 CANADA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018–2027 (USD MILLION)
TABLE 48 CANADA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018–2027 (USD MILLION)
TABLE 49 CANADA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018–2027 (USD MILLION)
TABLE 50 CANADA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, 2018–2027 (USD MILLION)
TABLE 51 CANADA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR TREATMENT TYPE, BY NUTRITION THERAPY, 2018–2027 (USD MILLION)
TABLE 52 CANADA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR A NUTRITION THERAPY, BY ANTIOXIDANTS, 2018–2027 (USD MILLION)
TABLE 53 CANADA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS, 2018–2027 (USD MILLION)
TABLE 54 CANADA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018–2027 (USD MILLION)
TABLE 55 CANADA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 56 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 57 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 58 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018-2027 (USD MILLION)
TABLE 59 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
TABLE 60 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
TABLE 61 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2018-2027 (USD MILLION)
TABLE 62 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2018-2027 (USD MILLION)
TABLE 63 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
TABLE 64 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 65 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 66 GERMANY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 67 GERMANY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018-2027 (USD MILLION)
TABLE 68 GERMANY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
TABLE 69 GERMANY: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
TABLE 70 GERMANY: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2018-2027 (USD MILLION)
TABLE 71 GERMANY: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2018-2027 (USD MILLION)
TABLE 72 GERMANY: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
TABLE 73 GERMANY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 74 GERMANY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 75 UK: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 76 UK: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018-2027 (USD MILLION)
TABLE 77 UK: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
TABLE 78 UK: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
TABLE 79 UK: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2018-2027 (USD MILLION)
TABLE 80 UK: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2018-2027 (USD MILLION)
TABLE 81 UK: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
TABLE 82 UK: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 83 UK: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 84 FRANCE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 85 FRANCE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018-2027 (USD MILLION)
TABLE 86 FRANCE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
TABLE 87 FRANCE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
TABLE 88 FRANCE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2018-2027 (USD MILLION)
TABLE 89 FRANCE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2018-2027 (USD MILLION)
TABLE 90 FRANCE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
TABLE 91 FRANCE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 92 FRANCE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 93 ITALY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 94 ITALY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018-2027 (USD MILLION)
TABLE 95 ITALY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
TABLE 96 ITALY: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
TABLE 97 ITALY: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2018-2027 (USD MILLION)
TABLE 98 ITALY: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2018-2027 (USD MILLION)
TABLE 99 ITALY: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
TABLE 100 ITALY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 101 ITALY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 102 SPAIN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 103 SPAIN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018-2027 (USD MILLION)
TABLE 104 SPAIN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
TABLE 105 SPAIN: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
TABLE 106 SPAIN: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2018-2027 (USD MILLION)
TABLE 107 SPAIN: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2018-2027 (USD MILLION)
TABLE 108 SPAIN: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
TABLE 109 SPAIN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 110 SPAIN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 111 REST OF EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 112 REST OF EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018-2027 (USD MILLION)
TABLE 113 REST OF EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
TABLE 114 REST OF EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
TABLE 115 REST OF EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2018-2027 (USD MILLION)
TABLE 116 REST OF EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2018-2027 (USD MILLION)
TABLE 117 REST OF EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
TABLE 118 REST OF EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 119 REST OF EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 120 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 121 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 122 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018-2027 (USD MILLION)
TABLE 123 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
TABLE 124 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
TABLE 125 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2018-2027 (USD MILLION)
TABLE 126 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2018-2027 (USD MILLION)
TABLE 127 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
TABLE 128 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 129 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 130 CHINA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 131 CHINA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018-2027 (USD MILLION)
TABLE 132 CHINA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
TABLE 133 CHINA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
TABLE 134 CHINA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2018-2027 (USD MILLION)
TABLE 135 CHINA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2018-2027 (USD MILLION)
TABLE 136 CHINA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
TABLE 137 CHINA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 138 CHINA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 139 JAPAN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 140 JAPAN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018-2027 (USD MILLION)
TABLE 141 JAPAN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
TABLE 142 JAPAN: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
TABLE 143 JAPAN: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2018-2027 (USD MILLION)
TABLE 144 JAPAN: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2018-2027 (USD MILLION)
TABLE 145 JAPAN: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
TABLE 146 JAPAN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 147 JAPAN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 148 INDIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 149 INDIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018-2027 (USD MILLION)
TABLE 150 INDIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
TABLE 151 INDIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
TABLE 152 INDIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2018-2027 (USD MILLION)
TABLE 153 INDIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2018-2027 (USD MILLION)
TABLE 154 INDIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
TABLE 155 INDIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 156 INDIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 157 SOUTH KOREA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 158 SOUTH KOREA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018-2027 (USD MILLION)
TABLE 159 SOUTH KOREA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
TABLE 160 SOUTH KOREA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
TABLE 161 SOUTH KOREA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2018-2027 (USD MILLION)
TABLE 162 SOUTH KOREA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2018-2027 (USD MILLION)
TABLE 163 SOUTH KOREA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
TABLE 164 SOUTH KOREA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 165 SOUTH KOREA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 166 AUSTRALIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 167 AUSTRALIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018-2027 (USD MILLION)
TABLE 168 AUSTRALIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
TABLE 169 AUSTRALIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
TABLE 170 AUSTRALIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2018-2027 (USD MILLION)
TABLE 171 AUSTRALIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2018-2027 (USD MILLION)
TABLE 172 AUSTRALIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
TABLE 173 AUSTRALIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 174 AUSTRALIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 175 REST OF ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 176 REST OF ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018-2027 (USD MILLION)
TABLE 177 REST OF ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018-2027 (USD MILLION)
TABLE 178 REST OF ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2018-2027 (USD MILLION)
TABLE 179 REST OF ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2018-2027 (USD MILLION)
TABLE 180 REST OF ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2018-2027 (USD MILLION)
TABLE 181 REST OF ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2018-2027 (USD MILLION)
TABLE 182 REST OF ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 183 REST OF ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 184 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION, 2018–2027 (USD MILLION)
TABLE 185 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018–2027 (USD MILLION)
TABLE 186 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018–2027 (USD MILLION)
TABLE 187 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018–2027 (USD MILLION)
TABLE 188 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, 2018–2027 (USD MILLION)
TABLE 189 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR TREATMENT, BY NUTRITION THERAPY, 2018–2027 (USD MILLION)
TABLE 190 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR NUTRITION THERAPY, BY ANTIOXIDANTS, 2018–2027 (USD MILLION)
TABLE 191 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS, 2018–2027 (USD MILLION)
TABLE 192 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018–2027 (USD MILLION)
TABLE 193 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 194 MIDDLE EAST: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018–2027 (USD MILLION)
TABLE 195 MIDDLE EAST: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018–2027 (USD MILLION)
TABLE 196 MIDDLE EAST: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018–2027 (USD MILLION)
TABLE 197 MIDDLE EAST: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, 2018–2027 (USD MILLION)
TABLE 198 MIDDLE EAST: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR TREATMENT TYPE, BY NUTRITION THERAPY, 2018–2027 (USD MILLION)
TABLE 199 MIDDLE EAST: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR A NUTRITION THERAPY, BY ANTIOXIDANTS, 2018–2027 (USD MILLION)
TABLE 200 MIDDLE EAST: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS, 2018–2027 (USD MILLION)
TABLE 201 MIDDLE EAST: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018–2027 (USD MILLION)
TABLE 202 MIDDLE EAST: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 203 AFRICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018–2027 (USD MILLION)
TABLE 204 AFRICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018–2027 (USD MILLION)
TABLE 205 AFRICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018–2027 (USD MILLION)
TABLE 206 AFRICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, 2018–2027 (USD MILLION)
TABLE 207 AFRICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR TREATMENT TYPE, BY NUTRITION THERAPY, 2018–2027 (USD MILLION)
TABLE 208 AFRICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR A NUTRITION THERAPY, BY ANTIOXIDANTS, 2018–2027 (USD MILLION)
TABLE 209 AFRICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS, 2018–2027 (USD MILLION)
TABLE 210 AFRICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018–2027 (USD MILLION)
TABLE 211 AFRICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 212 LATIN AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2018–2027 (USD MILLION)
TABLE 213 LATIN AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2018–2027 (USD MILLION)
TABLE 214 LATIN AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2018–2027 (USD MILLION)
TABLE 215 LATIN AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, 2018–2027 (USD MILLION)
TABLE 216 LATIN AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR TREATMENT TYPE, BY NUTRITION THERAPY, 2018–2027 (USD MILLION)
TABLE 217 LATIN AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR A NUTRITION THERAPY, BY ANTIOXIDANTS, 2018–2027 (USD MILLION)
TABLE 218 LATIN AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS, 2018–2027 (USD MILLION)
TABLE 219 LATIN AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2018–2027 (USD MILLION)
TABLE 220 LATIN AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 221 THE MOST ACTIVE PLAYERS IN THE GLOBAL DRY AMD MARKET
TABLE 222 CONTRACTS & AGREEMENTS
TABLE 223 NEW PRODUCT DEVELOPMENTS/LAUNCHES
TABLE 224 COLLABORATIONS/EXPANSIONS/PARTNERSHIPS/JOINT VENTURES
TABLE 225 INVESTMENT
TABLE 226 SANTEN PHARMACEUTICALS INC.: PRODUCTS/SERVICES OFFERED
TABLE 227 SANTEN PHARMACEUTICALS INC.: KEY DEVELOPMENTS
TABLE 228 ALLERGAN: PRODUCTS/SERVICES OFFERED
TABLE 229 BAUSCH HEALTH: PRODUCTS/SERVICES OFFERED
TABLE 230 BAUSCH HEALTH: KEY DEVELOPMENTS
TABLE 231 ALIMERA SCIENCES: PRODUCTS/SERVICES OFFERED
TABLE 232 RXI PHARMACEUTICALS, INC.: PRODUCTS/SERVICES OFFERED
TABLE 233 OCUMENSION THERAPEUTICS (SHANGHAI) CO., LTD: PRODUCTS/SERVICES OFFERED
TABLE 234 OCUMENSION THERAPEUTICS (SHANGHAI) CO., LTD: KEY DEVELOPMENTS
TABLE 235 BELITE BIO INC.: PRODUCTS/SERVICES OFFERED
TABLE 236 BELITE BIO INC.: KEY DEVELOPMENTS
TABLE 237 KUBOTA VISION INC.: PRODUCTS/SERVICES OFFERED
TABLE 238 IVERIC BIO: PRODUCTS/SERVICES OFFERED
TABLE 239 IVERIC BIO: KEY DEVELOPMENTS
TABLE 240 EYESTEM RESEARCH PVT LTD: PRODUCTS/SERVICES OFFERED
TABLE 241 YUYANG DNU CO., LTD: PRODUCTS/SERVICES OFFERED
TABLE 242 STEALTH BIOTHERAPEUTICS CORP: PRODUCTS/SERVICES OFFERED
TABLE 243 STEALTH BIOTHERAPEUTICS CORP: KEY DEVELOPMENTS
LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS
FIGURE 2 GLOBAL DRY AMD MARKET
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
FIGURE 4 MARKET DYNAMICS: DRY AGE-RELATED MACULAR DEGENERATION MARKET
FIGURE 5 DRIVER IMPACT ANALYSIS
FIGURE 6 RESTRAINT IMPACT ANALYSIS
FIGURE 7 VALUE CHAIN ANALYSIS: DRY AMD MARKET
FIGURE 8 PORTER’S FIVE FORCES ANALYSIS: DRY AMD MARKET
FIGURE 9 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2020 & 2027 (USD MILLION)
FIGURE 10 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2020 & 2027 (USD MILLION)
FIGURE 11 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2020 & 2027 (USD MILLION)
FIGURE 12 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2020 & 2027 (USD MILLION)
FIGURE 13 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2020 & 2027 (USD MILLION)
FIGURE 14 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION 2020 & 2027 (USD MILLION)
FIGURE 15 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET SHARE (%), BY REGION, 2020
FIGURE 16 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET SHARE (%), BY COUNTRY, 2020
FIGURE 17 EUROPE DRY AGE-RELATED MACULAR DEGENERATION MARKET SHARE (%), BY COUNTRY, 2020
FIGURE 18 ASIA-PACIFIC DRY AGE-RELATED MACULAR DEGENERATION MARKET SHARE (%), BY COUNTRY, 2020
FIGURE 19 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET SHARE (%), BY REGION, 2020
FIGURE 20 MAJOR MANUFACTURERS MARKET SHARE ANALYSIS (%), 2020
FIGURE 21 CONTRACTS & AGREEMENTS: THE MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL DRY AMD MARKET
FIGURE 22 BENCHMARKING OF MAJOR COMPETITORS
FIGURE 23 SALES, 2020
FIGURE 24 MAJOR PLAYERS R&D EXPENDITURE, 2020
FIGURE 25 SANTEN PHARMACEUTICALS INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 26 SANTEN PHARMACEUTICALS INC.: SWOT ANALYSIS
FIGURE 27 ALLERGAN: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 28 ALLERGAN: SWOT ANALYSIS
FIGURE 29 BAUSCH HEALTH: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 30 BAUSCH HEALTH: SWOT ANALYSIS
FIGURE 31 ALIMERA SCIENCES: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 ALIMERA SCIENCES: KEY DEVELOPMENTS
FIGURE 33 ALIMERA SCIENCES: SWOT ANALYSIS
FIGURE 34 RXI PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 RXI PHARMACEUTICALS, INC.: SWOT ANALYSIS
FIGURE 36 OCUMENSION THERAPEUTICS (SHANGHAI) CO., LTD: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 37 OCUMENSION THERAPEUTICS (SHANGHAI) CO., LTD: SWOT ANALYSIS
FIGURE 38 BELITE BIO INC.: SWOT ANALYSIS
FIGURE 39 KUBOTA VISION INC.: FINANCIAL OVERVIEW
FIGURE 40 KUBOTA VISION INC.: SWOT ANALYSIS
FIGURE 41 IVERIC BIO.: SWOT ANALYSIS
FIGURE 42 EYESTEM RESEARCH PVT Ltd: SWOT ANALYSIS
FIGURE 43 YUYANG DNU CO., LTD: SWOT ANALYSIS
FIGURE 44 STEALTH BIOTHERAPEUTICS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 45 STEALTH BIOTHERAPEUTICS CORP: SWOT ANALYSIS